Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report

Chie Iitake1*, Daisaku Masuda2,3, Masahiro Koseki4 and Shizuya Yamashita2

Abstract

Background: Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer from acute pancreatitis. Pemafibrate is a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα) which has been developed as an affordable oral tablet in Japan. We herein report the first three patients with severe hypertriglyceridemia who were successfully treated with pemafibrate.

Methods: Three patients with fasting serum triglyceride (TG) levels above 1,000 mg/dL (11.3 mmol/L) were treated with pemafibrate (0.2–0.4 mg/day, 0.1–0.2 mg BID).

Results: Serum TGs decreased from 2,000–3,000 mg/dL (22.6–33.9 mmol/L) to < 250 mg/dL (2.8 mmol/L) without adverse effects in all three patients. Serum TGs in Patient 1 and 2 decreased from 1,326 mg/dL (15.0 mmol/L) to 164 mg/dL (1.9 mmol/L) and from 2,040 mg/dL (23.1 mmol/L) to 234 mg/dL (2.6 mmol/L), respectively. Patient 3 with type 2 diabetes and 12.1% (109 mmol/mol) hemoglobin A1c had a TG level of 2,300 mg/dL (26.0 mmol/L). Even after glycemic control improved, TG remained high. After pemafibrate administration, TG decreased to 200 mg/dL (2.3 mmol/L). All patients showed no serious adverse events.

Conclusions: Pemafibrate demonstrated potential efficacy and safety for severe hypertriglyceridemia which may contribute to the prevention of acute pancreatitis, in a manner that can be easily prescribed and used as an oral tablet.

Keywords: Pparα, Spparmα, Pemafibrate, Severe hypertriglyceridemia, Hyperchylomicronemia, Familial chylomicronemia syndrome, Acute pancreatitis

Background

Treatment of patients with severe hypertriglyceridemia, in whom serum triglycerides (TGs) are > 1,000 mg/dL (11.3 mmol/L), is currently extremely challenging. The lowering of serum TGs to a reasonable level is crucial for preventing acute pancreatitis in patients with severe hypertriglyceridemia. Available treatments, including fibrates, niacin, and omega-3 polyunsaturated fatty acids, have only been partly successful. Clinical trials of fibrates have demonstrated some efficacy in patients with TG levels < 1,000 mg/dL (11.3 mmol/L) [1]. In a retrospective cohort study, most hypertriglyceridemic patients with a history of pancreatitis who were treated with fibrates had TG levels > 3,000 mg/dL (33.9 mmol/L) [2]. In these patients, rare dyslipidemic disorders are occasionally
included. Familial chylomicronemia syndrome (FCS) is caused by mutations in the lipoprotein lipase (LPL) and related molecules. FCS is often underdiagnosed and unmanaged [3]. Currently available fibrates such as gemfibrozil, fenofibrate, and bezafibrate were shown to be ineffective for severe hypertriglyceridemic patients with LPL deficiency whose clearance of chylomicrons from the plasma is markedly impaired [4]. Treatment outcomes have been suboptimal in patients with severe hypertriglyceridemia, and data on treatment options are limited.

Pemafibrate [5, 6], a novel selective peroxisome proliferator-activated receptor α (PPARα) modulator (SPPARMα) developed by Kowa Co. (Tokyo, Japan), is currently marketed since 2018 only in Japan. It is available as an affordable oral tablet, which is in contrast with the latest gene-targeted therapies that are very expensive and generally administered via injections. The efficacy of pemafibrate in hypertriglyceridemic patients has been shown in clinical trials [6] and general practice [7]. In the phase 3 trial [6], pemafibrate at doses of 0.2 and 0.4 mg/day (0.1 mg and 0.2 mg BID) significantly reduced TG levels from the baseline by 46.2% and 45.9%, respectively, compared with a reduction of 39.7% achieved with the administration of 106.6 mg/day fenofibrate. Currently available fibrates are often associated with adverse events, such as worsening of renal function and elevation of liver enzymes levels [8, 9]. Fenofibrate was shown to decrease both of them [6].

Treatment of severe hypertriglyceridemia for the prevention of acute pancreatitis is a significant challenge in patients with TG levels > 1,000 mg/dL (11.3 mmol/L). Episodes of relapsing acute pancreatitis can lead to chronic pancreatitis, as well as both exocrine and endocrine pancreatic insufficiency in the future [10]. But no study to date has verified the efficacy of pemafibrate in these patients. The PROMINENT trial, currently ongoing worldwide, aims to evaluate the efficacy of pemafibrate in preventing cardiovascular events in high-risk diabetic patients, although the trial excludes patients with TGs > 500 mg/dL (5.6 mmol/L) [11]. The present report of three patients with severe hypertriglyceridemia is the first ever evidence that pemafibrate can dramatically reduce very high serum TG levels > 1,000 mg/dL (11.3 mmol/L).

Methods

Patients

Patient 1 was treated in Rinku General Medical Center, Izumisano/Osaka, Japan. Patient 2, in Osaka University Hospital, Suita/Osaka, Japan. Patient 3, at Iitake Clinic for Internal Medicine, Mito/Ibaraki, Japan. All patients had a history of high serum TG levels > 2,000 mg/dL (22.6 mmol/L). Patients 1 and 2 were never medicated before, and Patient 3 partially responded to fibrate therapy in the past but suspended this treatment for a long time. Patient 3 also had a history of acute pancreatitis.

Baseline treatment

All patients were placed on a fat restriction diet according to the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Disease 2017 [12] and had regularly scheduled visits with their doctors. Other fibrates, statins and omega-3 polyunsaturated fatty acids were not used before or during pemafibrate treatment.

Pemafibrate treatment

The pemafibrate dose was determined by the treating physician. The standard pemafibrate dose was 0.2 mg/day (0.1 mg BID) and could be increased to 0.4 mg/day (0.2 mg BID). However, down-titration was considered for patients with liver dysfunction, as 0.1 mg once daily.

Pharmacodynamic and genetic assessment

Laboratory data were collected from electronic patient health records. Blood samples were obtained under fasting conditions. Genetic testing was performed in Patient 2 and is currently under investigation in Patient 1. No genetic testing was performed in Patient 3.

Results

Patient 1 (Fig. 1a) was a 49-year-old female who was diagnosed at a local clinic with severe hypertriglyceridemia at the age of 47 years. Her serum TG level was 2,511 mg/dL (28.4 mmol/L), and she had neither diabetes nor a history of acute pancreatitis. She was referred to Rinku General Medical Center. At the age of 30, her TG level was approximately 800 mg/dL (9.0 mmol/L) but was left untreated. She was an occasional alcohol drinker with a body mass index (BMI) 25.4 kg/m². She was considered to have familial LPL deficiency based on a reduced LPL activity time. Patient 3 also had a history of acute pancreatitis. Her mother also had severe hypertriglyceridemia, suggesting that they may have a dominant genetic mutation.

Despite strict dietary fat restriction for 5 months, her serum TG levels exceeded 1,000 mg/dL (11.3 mmol/L). Thus, pemafibrate (0.4 mg/day, 0.2 mg BID) treatment was initiated. Her TG level decreased from 1,326 mg/dL (15.0 mmol/L) to 173 mg/dL (2.0 mmol/L) in one month. She discontinued pemafibrate due to a migraine attack during menstruation, which increased her serum...
Fig. 1 Effects of pemafibrate on serum triglyceride in patients with severe hypertriglyceridemia. a Patient 1, b Patient 2, c Patient 3. Day 0 is the baseline when pemafibrate was administered. In Patient 2, after the first administration, the patient was not compliant to take the drug. Nearly 200 days after the treatment, he suspended taking pemafibrate. Approximately after 300 days, he restarted to take pemafibrate regularly.

Triglyceride (mg/dL), HDL-C (mg/dL)
Patient 2 (Fig. 1b) was a 21-year-old male diagnosed with hypertriglyceridemia at the age of 15 years in a nearby clinic. Due to worsening eating habits at the age of 19 years, his TG level increased to >2,500 mg/dL (28.3 mmol/L) over 8 months. He was referred to Osaka University Hospital. He occasionally consumed alcohol and was not obese (BMI, 23.6 kg/m²). He did not have diabetes or a history of acute pancreatitis. We identified homozygous mutation of c.553G > T in APOA5 gene, which was reported to be pathogenic and homozygotes manifest severe hypertriglyceridemia (mean TG = 2 292 ± 447 mg/dL) [13]. Patients 2's father was a heterozygote of this mutation and also had hypertriglyceridemia.

After 8 months of strict dietary fat restriction, pemafibrate (0.4 mg/day, 0.2 mg BID) was initiated. Serum TG level dropped from 2,040 mg/dL (22.6 mmol/L) to 392 mg/dL (4.4 mmol/L). However, he often missed taking pemafibrate, which led to elevated TG levels at 1,000–2,800 mg/dL (11.3 to 31.6 mmol/L). Nevertheless, his TG level was decreased to 234 mg/dL (2.6 mmol/L) after resuming regular pemafibrate treatment.

Patient 3 (Fig. 1c), a 43-year-old male diagnosed with hypertriglyceridemia at the age of 39 years in another clinic, was referred to Iitake Clinic for Internal Medicine with worsening diabetes. His fasting plasma glucose and hemoglobin A1c (HbA1c) levels were 297 mg/dL (16.5 mmol/L) and 10.3% (89 mmol/mol), respectively. He was diagnosed with type 2 diabetes. Dietary restriction and physical exercise were initiated. Despite initial improvement in laboratory parameters, he often interrupted the therapeutic lifestyle measures. When he returned 9 months after diagnosis, fasting plasma glucose, HbA1c, and TG levels were 239 mg/dL (13.3 mmol/L), 12.1% (109 mmol/mol), and 2,300 mg/dL (26.0 mmol/L), respectively. He had a history of acute pancreatitis, and liver dysfunction. He was consuming Japanese sake 2–3 alcohol units daily. His BMI was 28.2 kg/m². His father had hypertriglyceridemia and type 2 diabetes.

Canagliflozin (100 mg/day) was initiated for glycemic control, and teneligliptin (20 mg/day) was added, which reduced HbA1c to 7.9% (63 mmol/mol) in 5 months. However, his TG level remained high at 2,300 mg/dL (26.0 mmol/L). A low pemafibrate dose (0.1 mg once daily) was initiated due to the history of liver dysfunction. After 1 month, his TG level dropped to 780 mg/dL (8.8 mmol/L). No adverse effects were observed, and pemafibrate was increased to 0.2 mg/day (0.1 mg BID). Serum TG level further decreased to 200 mg/dL (2.3 mmol/L), and HbA1c remained around 7.5% (58 mmol/mol). No correlation was noted between serum TG levels and glycemic control. For Patient 3, we could not perform a genetic testing.

Regarding the changes in serum HDL-C level, the improvement of serum TG level was generally associated with an increase in serum HDL-C level (Fig. 1) and a moderate increase in LDL-C level (Additional file 1: Figure S1). It is also very important to better characterize the safety of pemafibrate. Changes of liver and muscle enzymes, creatinine values as well as glucose and HbA1c are also shown in Additional file 1: Table S1. Pemafibrate was safe in terms of liver and kidney functions as well as glucose metabolism.

**Discussion**

There are no effective therapies for severe hypertriglyceridemia at present. Alipogene tiparvovec (Glybera®) [14], the first gene therapy for patients with familial LPL deficiency, was withdrawn from the market due to its extremely high cost and insufficient TG-lowering effect. Messenger RNA (mRNA) antisense and RNA interference approaches have been evaluated to modulate the levels of apolipoprotein C3 (apo C3), a potential new drug target for patients with FCS. Volanesorsen (ISIS 304,801, formerly INOS APOCIIIRx), a second-generation 2'-O-(2-methoxyethyl)-modified antisense inhibitor of apo C3 synthesis, was effective in three patients and reduced their TG levels to <500 mg/dL (5.7 mmol/L) [15]. A recent study reported that antisense-mediated inhibition of hepatic apolipoprotein C3 (APOCH3) mRNA with volanesorsen led to reduced plasma levels of apo C3 and TGs. Specifically, serum TG levels were reduced to <750 mg/dL (8.5 mmol/L) in most patients with FCS [16]. Inhibition of angiopoietin-like protein 3 (Angptl 3) may be another target for FCS. Monoclonal antibodies (evinacumab, Regeneron Pharmaceuticals) [17], antisense oligonucleotides (AKCEA-ANGPTL3-LRx, Akcea Therapeutics; formerly IONIS-ANGPTL3-LRx) [18] and RNA interference (ARO-ANG3, Arrowhead Pharmaceuticals) [19] have been investigated. However, most of the new gene therapies are administered via injection and remain expensive, which hinder their applicability in many patients. Therefore, effective and cheaper strategies may be crucial for treating severe hypertriglyceridemia.

Our three patients demonstrate the efficacy of pemafibrate, reducing TG levels from above 2,000 mg/dL (22.6 mmol/L) to below 250 mg/dL (2.8 mmol/L). Potential mechanisms underlying the effects observed in these patients are illustrated in Fig. 2. We speculate
that underlying TG-lowering mechanisms may be distinct from those of conventional fibrates. Pemafibrate enhances LPL activity by PPARα-mediated increase in LPL synthesis and a reduction in apo C3, thereby promoting the catabolism of chylomicrons, very low-density lipoprotein (VLDL), and their TG-rich remnants. Our three patients did not have a complete, but only partial, deficit in LPL, which may be one of the reasons why pemafibrate was effective. However, we also speculate the possibility that there might be other pathways not mediated by enhanced LPL. In future studies, we could also test the effect of pemafibrate on serum TG levels in patients with complete LPL deficiency.

Pemafibrate enhances β-oxidation of fatty acids and suppresses the hepatic synthesis of TG and VLDL. Therefore, pemafibrate reduces not only serum TG but also chylomicron/VLDL remnants and small dense low-density lipoprotein (LDL) cholesterol, concomitantly increasing high density lipoprotein (HDL) cholesterol. Pemafibrate also inhibits the synthesis and secretion of chylomicrons from the small intestine [20]. It was also shown to suppress postprandial hyperlipidemia more strongly than fenofibrate in mice fed a high-fat diet by inhibiting mRNA expression of apolipoprotein B-48 (APOB-48), intestinal cholesterol transporter Nieman-Pick C1-like 1 (NPC1L1) and microsomal triglyceride transfer protein in the small intestine.

Conclusions
The striking reduction in serum TG by pemafibrate may reduce the risk of acute pancreatitis in patients with markedly raised TG, which has not been achieved with currently available therapeutics. Moreover, pemafibrate is very affordable by prescription and is easy to administer as an oral tablet. Our experience from this proof-of-concept study in three patients may shed a new light into the management of patients with severe hypertriglyceridemia.

Limitations
This is a small sample study of only three patients. Patients 1 and 2 had a transient suspension of taking pemafibrate, which may make the effectiveness of pemafibrate vague. However, after restarting pemafibrate, both cases showed a rapid reduction of TG, suggesting the sharp activation of PPARα by pemafibrate.

In our three cases, a genetic testing was performed only in one case (Patient 2) and homozygous mutation in the APOA5 was identified. However, patients with extremely high serum TG levels may have a
possibility of genetic disorders. Mutations of genes such as APOC2, GPIHBP1, LMF1, APOA5 are already commonly known and it may be feasible to identify mutations in other two cases. However, inadequate lifestyle perhaps had a bigger influence on serum TG levels than genetic and polygenic mutations. In the future study, we may need to recruit more patients with hyperchylomicronemia and perform a case–control trial with genetic profiles.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12933-020-01172-8.

Additional file 1: Table S1. Changes of serum lipids, liver function/renal function tests before and after treatment with pemafibrate.

Abbreviations
APOA5: Apolipoprotein A5; APOB-48: Apolipoprotein B-48; APOC2: Apolipoprotein C2; APOC3: Apolipoprotein C3; FCS: Familial chylomicronemia syndrome; GPIHBP1: Glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; LMF1: Lipase maturation factor 1; LPL: Lipoprotein lipase; mRNA: Messenger RNA; Npc1L1: Nieman-Pick C1-like 1; PPARa: Peroxisome proliferator-activated receptor α; SPPARMα: Selective peroxisome proliferator-activated receptor α modulator; TG: Triglyceride; VLDL: Very low-density lipoprotein.

Acknowledgements
We thank the patients and their families, as well as the clinical staff at each facility for supporting patient care and treatment to conduct this study. The authors thank Enago (www.enago.jp) for the English language review.

Authors’ contributions
C.J. wrote the first draft and S.Y supported the editing. All authors are responsible for the revisions and have approved the final version to be submitted. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Each patient was given enough information about the aim and concept of the study and agreed to provide their laboratory data in an unidentified form.

Consent for publication
Not applicable.

Competing interests
S.Y reports a lecture fee and M.K. reports a grant from Kowa Co. during the conduct of the study.

Author details
1 Iitake Clinic for Internal Medicine, 2131-1976 Migawacho, Mito City, Ibaraki 310-0913, Japan. 2 Department of Cardiology, Rinku General Medical Center, 2-23 Ourai- kita, Rinku, Izumisano, Osaka 598-0048, Japan. 3 Rinku Innovation Center for Wellness Care and Activities (RICWA), Rinku General Medical Center, 2-23 Ourai- kita, Rinku, Izumisano, Osaka 598-0048. Japan. 4 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka,Suita, Osaka 565-0871, Japan.

Received: 19 August 2020 Accepted: 15 November 2020
Published online: 27 November 2020

References
1. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.
2. Sandhu S, Al-Sarraf A, Tarabontaa C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011;10:157.
3. James MF. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract. 2018;24:756–63.
4. Brisson D, Méthot J, Tremblay K, Tremblay M, Perron P, Gaudet D. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics. 2010;20:742–7.
5. Fruchtman CL, Santos RD, Aguilar-Salinac C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18:71.
6. Ishibashi S, Arai H, Yokoie K, Arai E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor a modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173–84.
7. Iitake C, Iitake K. Half dose once-daily pemafibrate effectively improved hypertriglyceridemia in real practice. J Clin Med Res. 2019;11:1190–5.
8. Ncube V, Starkey B, Wang T. Effect of fenofibrate treatment for hyperlipidemia on serum creatinine and cystatin C. Ann Clin Biochem. 2012;49:491–3.
9. Hedrington MS, Davis SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol. 2018;14:671–7.
10. Sarnan G, Erzin Y, Hatermi I, et al. Familial chylomicronemia syndrome related chronic pancreatitis: a single-center study. Hepatobiliary Pancreat Dis Int. 2014;13:209–14.
11. Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMISEN) study. Am Heart J. 2018;206:80–93.
12. Kinosita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25:846–984.
13. Pullinger CR, Aouizerat BE, Movsesyan I, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res. 2008;49:1846–54.
14. Gaudet D, Méthot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23:310–20.
15. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200–6.
16. Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531–42.
17. Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211–21.
18. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222–32.
19. Arrowhead Pharmaceuticals. Pipeline: Novel drugs to treat intractable diseases (https://arrowheadpharma.com/pipeline/) (Accessed on 29 October, 2020).
20. Saiyo M, Kobayashi T, Masuda D, et al. A novel selective PPARα modulator (PPARα-M), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J Atheroscler Thromb. 2018;25:142–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.